Download Free Medical Understanding Sleep Disorders For The Clinician PowerPoint Presentation

Understanding Sleep Disorders For The Clinician PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Understanding Sleep Disorders for the Clinician” by Lisa Cottrell, Ph.D., CBSM, DBSM.

This medical PowerPoint presentation is about sleep disorders which can have a significant impact on an individuals health and quality of life. As a clinician, its important to understand the various types of sleep disorders, their symptoms, causes, and treatment options.

Insomnia: Insomnia is a common sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early. It can be caused by a variety of factors, including stress, anxiety, depression, medication side effects, or medical conditions. Treatment may involve cognitive-behavioral therapy, medication, or a combination of both.
Sleep Apnea: Sleep apnea is a sleep disorder characterized by pauses in breathing during sleep. This can result in loud snoring, gasping, or choking sounds during the night. It can be caused by obesity, smoking, alcohol consumption, or structural abnormalities in the airway. Treatment may involve lifestyle changes, such as weight loss or quitting smoking, or the use of a continuous positive airway pressure (CPAP) machine.
Restless Leg Syndrome (RLS): RLS is a neurological disorder characterized by an uncontrollable urge to move the legs, particularly during periods of rest or inactivity. It can be caused by iron deficiency, kidney failure, or other medical conditions. Treatment may involve medication or lifestyle changes, such as exercise or avoiding caffeine.
Narcolepsy: Narcolepsy is a neurological disorder characterized by excessive daytime sleepiness, sudden sleep attacks, and other symptoms such as cataplexy (a sudden loss of muscle tone). It can be caused by a genetic predisposition or autoimmune disorder. Treatment may involve medication or lifestyle changes, such as regular sleep and nap schedules.
Circadian Rhythm Disorders: Circadian rhythm disorders are a group of sleep disorders that affect the timing of sleep and wakefulness. They can be caused by shift work, jet lag, or irregular sleep schedules. Treatment may involve lifestyle changes, such as regular sleep and wake times or light therapy.

Its important for clinicians to be aware of these sleep disorders and their potential impact on patients health and quality of life. Referring patients to a sleep specialist may be necessary for accurate diagnosis and effective treatment.

Tags : Sleep Disorders, Insomnia, Sleep Apnea, Restless Leg Syndrome, Narcolepsy, Circadian Rhythm Disorders, Neurology, Neurology PowerPoint presentation

Published on : Jun 20, 2023 | Views : 1017 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Lisa Cottrell, Ph.D., CBSM, DBSM Understanding Sleep Disorders for the Clinician Part 2
Slide 2-

Non-Sleep Disorders in the DSM-5 that Involve Sleep Manic/hypomanic Episodes Major Depressive Episode Premenstrual Dysphoric Disorder Melancholic Features Generalized Anxiety Disorder Posttraumatic Stress Disorder Alcohol Withdrawal Caffeine Intoxication Cannabis Withdrawal Opioid Withdrawal Sedative, Hypnotic, Anxiolytic Withdrawal Stimulant Withdrawal Tobacco Withdrawal
Slide 3-

Sleep Disorders in the DSM-5 Insomnia Disorder Hypersomnia Disorder Narcolepsy Obstructive Sleep Apnea Central Sleep Apnea Sleep-Related Hypoventilation Circadian Rhythm Sleep Wake Disorders Non-REM Sleep Arousal Disorders Nightmare Disorder REM Sleep Behavior Disorder Restless Legs Syndrome Substance/Medication – Induced Sleep Disorder
Slide 4-

ppt slide no 4 content not found
Slide 5-

Insomnia DSM-5 “Insomnia Disorder” Dissatisfaction with sleep quantity/quality Initiation, maintenance or early morning waking Clinically significant distress Minimum 3 nights/week Minimum 3 months Adequate sleep opportunity Not better explained or exclusively during the course of another sleep-wake disorder Not caused by substance Coexisting conditions don’t adequately explain Specify: with non-sleep mental comorbidity; with other medical comorbidity; with other sleep disorder
Slide 6-

ICSD-3 “Chronic Insomnia Disorder” One or more difficulty Initiating sleep Maintaining sleep Waking too early Resistance to appropriate bedtime Difficulty sleeping without parent or caregiver intervention Related to sleep difficulty, one or more Fatigue Attention/concentration/memory impairment Social/family/occupational/academic impairment Mood disturbance Daytime sleepiness Behavioral problems Reduced motivation Error proneness Dissatisfaction with/concerns about sleep Not explained by inadequate sleep opportunity 3 times per week 3 months Not better explained by another sleep disorder
Slide 7-

ppt slide no 7 content not found
Slide 8-

Insomnia Diagnosis Clinical interview, includes sleep history and rule out of other sleep disorders Data collection – sleep diary Actigraph Standardized measures: e.g., Insomnia Severity Index, Dysfunctional Attitudes and Beliefs about Sleep
Slide 9-

Insomnia Treatment Cognitive-Behavioral Treatment of Insomnia (CBTI) Medication Cognitive-Behavioral treatment with complementary therapies Behavior Activation Activity-Rest-Pacing Multiple relaxation methods Bright light therapy/melatonin Mindfulness Online Cognitive-Behavioral Treament
Slide 10-

ppt slide no 10 content not found
Slide 11-

Insomnia Treatment - Medication Anecdotally, chronic patients report decreasing efficacy of most hypnotics and sedating medications and they often prefer not to take them Psychological dependence is frequently an issue, rebound insomnia can be an issue in discontinuation Medication issues complicated by comorbid psychiatric tx Most commonly prescribed are benzodiazepine receptor agonists, including benzodiazepines (e.g., temazepam, lorazepam, alprazolam) and non-benzodiazepine agents that act on the same site on the GABA-A receptor complex (e.g., zolpidem, eszopiclone, zaleplon) Sedating antidepressant drugs such as trazodone as well as sedating tricyclic antidepressants (e.g., doxepin, imipramine, nortriptyline, clomipramine, amitriptyline) are widely used Melatonin agonist ramelteon Melatonin Diphenhydramine Suvorexant (dual orexin receptor antagonist)
Slide 12-

Evidence for the Efficacy of CBTI Decades of research evidence that convincingly demonstrates the efficacy of CBTI (e.g., Edinger & Carney, 2008; Espie, 2002) as the “well established and proven” treatment approach CBTI is just as effective as sedating hypnotics during acute treatment (4-8 weeks) (e.g., Smith et al., 2005) CBTI is more effective than sedating hypnotics long-term (e.g., Espie et al., 2001; Morin et al., 2006) CBTI has been established as the first line treatment approach for insomnia (Smith et al., 2002) CBTI is more effective than zolpidem (Jacobs et al., 2004) CBTI is more effective than zopiclone (Sivertsen et al., 2006) When given the option, people prefer CBTI to pharmacotherapy for insomnia (Morin et al., 1992) and patients report greater satisfaction with CBTI and rate it as more effective than sleep medication (Morin et al., 1999)
Slide 13-

Some techniques used in CBTI Sleep education Motivational interviewing Sleep scheduling Sleep restriction Cognitive therapy Relaxation training Mindfulness Self monitoring Activity scheduling
Slide 14-

ppt slide no 14 content not found
Slide 15-

Components of CBTI Behavioral Stimulus control Sleep restriction therapy Both must be used cautiously and with appropriate understanding of factors that impact patient safety as well as full sleep assessment Cognitive Thoughts and beliefs about sleep Address dysfunctional thoughts and educate patient
Slide 16-

ppt slide no 16 content not found
Slide 17-

Obstructive Sleep Apnea DSM-5 “ Obstructive Sleep Apnea Hypopnea” Either 1 or 2 (1)Evidence by polysomnography of at least 5 obstructive sleep apneas &/or hypopneas AND snoring, snorting, breathing pauses OR daytime sleepiness not attributable to inadequate sleep opportunity or another medical/mental condition (2)Evidence by polysomnography of 15 or more apneas &/or hypopneas Rated by events per hour: mild (<15), moderate (15-30) or severe (>30)
Slide 18-

ICSD-3 “Obstructive Sleep Apnea, Adult” (A and B) or C (A) One or more of the following: Sleepiness/nonrestorative sleep/fatigue/insomnia Observer reports snoring/breathing interruptions Patient wakes breath holding, gasping, choking Diagnosis of mood disorder, hypertension, cognitive dysfunction, coronary artery disease, stroke, congestive heart failure, atrial fibrillation, T2 diabetes (B) PSG demonstrates 5 or more predominantly obstructive respiratory events (C) PSG or OCST demonstrates 15 or more predominantly obstructive respiratory events per hour
Slide 19-

ICSD-3 “Obstructive Sleep Apnea, Pediatric” Presence of one or more of the following: Snoring Labored or obstructed breathing during sleep Sleepiness/hyperactivity/behavioral problems/learning problems AND PSG demonstrates One or more apneas/hypopneas per hour of sleep OR A pattern of obstructive hypoventilation
Slide 20-

Obstructive Sleep Apnea Treatment Estimated 60% of moderate to severe OSA is attributable to obesity; in those cases, weight loss may reduce or eliminate the OSA Positive airway pressure still most common treatment (CPAP, BiPAP, AutoPAP) Dental device (OPT, oral pressure treatment) UPPP (surgery) Patient compliance is a key factor. Anxiety and claustrophobic reactions can reduce PAP therapy compliance. Appropriate gradual desensitization treatment can be effective to address those concerns.
Slide 21-

Latest treatments for OSA Hypoglossus Nerve Stimulation A relatively new advancement (approved by the FDA in 2014), a small device is surgically implanted in the chest, and can be turned on and off by the patient. While you sleep, the device monitors your breathing and stimulates a nerve that keeps the upper airway open. Initial research has shown that HGS improved patients’ symptoms, and had few side effects and good compliance. Doctors may recommend this therapy for patients with moderate to severe obstructive sleep apnea who are not helped by PAP therapy. Expiratory Positive Airway Pressure (EPAP) The EPAP system uses disposable adhesive valves that are placed over the nose when you sleep. When you inhale, the valve opens and helps the airway remain unobstructed. When you exhale, the airflow is directed into small channels, which creates pressure and, again, keeps the airways open. Open airways mean fewer incidences of obstructed breathing and interruptions in sleep. Initial research has shown EPAP therapy has a high level of adherence—a good sign for successful OSA treatment. Source: National Sleep Foundation
Slide 22-

ppt slide no 22 content not found
Slide 23-

Circadian Rhythm Sleep Wake Disorders DSM-5 subtypes: Delayed sleep phase Advanced sleep phase Irregular sleep wake type Non 24 hour type Shift work type Unspecified type
Slide 24-

ICSD-3 Circadian Rhythm Sleep-Wake Disorders Delayed Sleep-Wake Phase Disorder Advanced Sleep-Wake Phase Disorder Irregular Sleep-Wake Rhythm Disorder Non-24 –Hour Sleep Wake Rhythm Disorder Shift Work Disorder Jet Lag Disorder Circadian Sleep-Wake Disorder Not Otherwise Specified
Slide 25-

Treatment of Circadian Rhythm Sleep Wake Disorders Light Activity scheduling Nap scheduling Melatonin Ramelteon Stimulant medications (???) Sedating/hypnotic medications (???)
Slide 26-

Parasomnias Non-REM parasomnias: Disorders of arousal Confusional arousals Sleepwalking Sleeptalking Sleep terrors Sleep related eating disorder REM related parasomnias: REM Sleep Behavior Disorder Recurrent isolated sleep paralysis Nightmare disorder Other parasomnias include sleep enuresis, sleep related hallucinations and exploding head syndrome Differential diagnosis may require overnight sleep study but can often be made based on specific symptoms
Slide 27-

Narcolepsy DSM-5 specifies with and without cataplexy, hypocretin deficiency, autosomal dominant subtypes, secondary to medical condition ICSD-3 specifies Type 1 and Type 2 narcolepsy among other central disorders of hypersomnolence Diagnosis requires polysomnography and/or measurement of CSF hypocretin concentration Treatment may include antidepressant medications that suppress REM, sodium oxibate, lifestyal and behavioral changes, activity scheduling and scheduled naps
Slide 28-

May require medication and/or medical management: Hypersomnia Disorder Central Sleep Apnea Sleep-Related Hypoventilation Restless Legs Syndrome Substance/Medication – Induced Sleep Disorder
Slide 29-

Thank you! “When I woke up this morning, my girlfriend asked me, “Did you sleep good?” I said, “No, I made a few mistakes.” Stephen Wright
Slide 30-

References American Academy of Sleep Medicine (2016) AASM invites public comment on draft clinical practice guideline for pharmacological treatment of chronic insomnia. An American Academy of sleep medicine practice guideline (draft). Advance online publication. Retrieved from http://www.aasmnet.org/articles.aspx?id=6241 American Academy of Sleep Medicine (2014). The International Classification of Sleep Disorders (3rd Ed.) Westchester, IL: The American Academy of Sleep Medicine. American Academy of Sleep Medicine (2014). The International Classification of Sleep Disorders (3rd Ed.) Darien, IL: The American Academy of Sleep Medicine Carney, C., & Manber, R. (2009). Quiet Your Mind and Get To Sleep. Oakland, CA: New Harbinger Publications, Inc. Edinger, J. & Carney, C. (2008). Overcoming Insomnia: A Cognitive-Behavioral Therapy Approach. New York: Oxford university Press, Inc. Espie, C. (2002). Insomnia: Conceptual issues in the development, persistence, and treatment of sleep disorder in adults. Annual Review of Psychology, 53, 215-243. Espie CA, Inglis SJ, Harvey L. (2001). Predicting clinically significant response to cognitive behavior therapy for chronic insomnia in general medical practice: Analyses of outcome data at 12 months posttreatment. Journal of Consulting and Clinical Psychology, 69, 58–66. Jacobs, G., Pace-Schott, E., Stickgold, R., & Otto, M. (2004). Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Archives of Internal Medicine, 164(17), 1888-96. Khurshid, K. (2015). A review of changes in DSM-5 sleep wake disorders. Psychiatric Times, 32(9). Kryger, M. H. (2010). Atlas of Clinical Sleep Medicine. Philadelphia, PA: Saunders Elsevier. Krystal, A. D. (2012). Psychiatric disorders and sleep. Neurologic Clinics, 30(4), 1389–1413. Morin, C., Bastien, C., Guay, B., Radouco-Thomas, M., Leblance, J., & Vallieres, A. (2004). Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. American Journal of Psychiatry, 161(2), 332-342. Morin C., Bootzin R., Buysse D., Edinger J., Espie C., & Lichstein , K. (2006). Psychological and behavioral treatment of insomnia: Update of the recent evidence (1998-2004). Sleep, 29(11), 1398-414. Morin, C., Colecchi, C., Stone, J., Sood, R., & Brink, D. (1999). Behavioral and pharmacological therapies for late-life insomnia: A randomized controlled trial. Journal of the American Medical Association, 281, 991–999.
Slide 31-

References (cont’d) Morin, C. & Espie, C. (2004). Insomnia: A Clinical Guide to Assessment and Treatment. New York: Springer Science + Business Media, LLC. Morin, C., Gaulier, B., Barry, T., & Kowatch, R. (1992). Patients’ acceptance of psychological and pharmacological therapies for insomnia. Sleep: Journal of Sleep Research & Sleep Medicine,15, 302-305. Perlis, M., Jungquist, C., Smith, M., & Posner, D. (2005). Cognitive Behavioral Treatment of Insomnia. New York: Springer. Qaaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, E. (2016). Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-139. Sivertsen, B., Omvik, S., Pallesen, S., Bjorvatn, B., Havik, O., Kvale, G., Nielsen, G., & Nordhus, I. (2006). Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA, 295(24), 2851-8. Smith, M., Huang, M. , & Manber, R. (2005). Cognitive behavior therapy for chronic insomnia occurring within the context of medical and psychiatric disorders. Clinical Psychology Review, 25(5), 559-592. Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, et al. (2002). Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. American Journal of Psychiatry, 159, 5–11. Watson NF, Badr MS, Belenky G, Bliwise DL, Buxton OM, Buysse D, Dinges DF, Gangwisch J, Grandner MA, Kushida C, Malhotra RK, Martin JL, Patel SR, Quan SF, Tasali E. (2015). Joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society on the recommended amount of sleep for a healthy adult: Methodology and discussion. Sleep 38(8):1161-83. Wright, K. P. (Ed.) (2009). Circadian rhythm sleep disorders. Sleep Medicine Clinics, 4(2), 1-311.